Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients - ROUSSELOT, P; LABAUME, S; MAROLLEAU, J.-P; LARGHERO, J; NOGUERA, M.-H; BROUET, J.-C; FERMAND, J.-P (Cancer research (Chicago, Ill.), 1999)
Keywords: Antineoplastic agents; Antineoplastic Agents - toxicity; Apoptosis - drug effects; Arsenic Poisoning; Arsenicals; Biological and medical sciences; Cell Division - drug effects; Cell Line; Cell Survival - drug effects; Chemotherapy; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Humans; Kinetics; Lymphocyte Activation; Medical sciences; Melarsoprol - toxicity; Multiple Myeloma - blood; Multiple Myeloma - immunology; Neoplasm Proteins - analysis; Neoplasm Proteins - biosynthesis; Nuclear Proteins - analysis; Oxides - toxicity; Pharmacology. Drug treatments; Plasma Cells - cytology; Plasma Cells - drug effects; Plasma Cells - pathology; Promyelocytic Leukemia Protein; Transcription Factors - analysis; Transcription Factors - biosynthesis; Tumor Suppressor Proteins; Human; Immunopathology; Melarsoprol; Arsenic trioxide; Cytotoxicity; Malignant hemopathy; Myeloma; In vitro; Immunoglobulinopathy; B-Cell; Lymphoproliferative syndrome; Established cell line; Mechanism of action; Tumor cell; Apoptosis